Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

UK online pharmacies must follow stricter regulations when prescribing weight-loss jabs, according to new General Pharmaceutical Council (GPhC) rules. The clampdown comes after several reports of ...

Share on Pinterest LeoPatrizi/Getty Images Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. Currently, only Wegovy is approved for weight loss in the United States.

One participant in the trial that reported in December said she repeatedly fainted during her first six months on CagriSema. Over the 68-week ... STEP trial, which studied semaglutide for weight ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

CQC and other medical professional bodies to ensure that the appropriate safeguards are in place for this new generation of weight loss drugs. "Further clarity on the provision and advertising of ...